Elypta
Elypta develops a metabolism-based liquid biopsy platform for cancer detection, measuring the GAGome (glycosaminoglycan biomarkers of tumor metabolism) and using machine learning to detect cancer signatures noninvasively. The company's MIRAM Kit enables analysis of urine and blood samples, with clinical studies showing game-changing potential in kidney cancer follow-up and the ability to predict risk of developing…
Funding snapshot
About
Elypta develops a metabolism-based liquid biopsy platform for cancer detection, measuring the GAGome (glycosaminoglycan biomarkers of tumor metabolism) and using machine learning to detect cancer signatures noninvasively. The company's MIRAM Kit enables analysis of urine and blood samples, with clinical studies showing game-changing potential in kidney cancer follow-up and the ability to predict risk of developing any-type cancer with a simple urine test. Elypta is a main partner in PREDI-LYNCH, a pan-European hereditary multi-cancer screening project that received 13.6 million euros in EU funding. Founded in 2017 and headquartered in Stockholm, Sweden, the company has raised approximately $27.9M in Series A funding. Elypta differentiates itself through its novel metabolism-based approach to liquid biopsy, using system biomarkers rather than tumor-derived DNA, enabling earlier cancer detection and recurrence monitoring across multiple cancer types.
Business model
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Differential Diagnosis > Bio Chemical and molecular tests > Molecular Profile > Genomics - AI,
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.